Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-920
Closed -$222K 132
2023
Q1
$222K Hold
920
0.03% 128
2022
Q4
$242K Hold
920
0.03% 132
2022
Q3
$212K Hold
920
0.03% 123
2022
Q2
$228K Hold
920
0.03% 123
2022
Q1
$234K Hold
920
0.03% 124
2021
Q4
$217K Buy
+920
New +$194K 0.02% 138
2021
Q3
Sell
-920
Closed -$224K 141
2021
Q2
$224K Hold
920
0.03% 138
2021
Q1
$230K Buy
+920
New +$220K 0.03% 135
2020
Q4
Sell
-920
Closed -$217K 140
2020
Q3
$217K Hold
920
0.03% 125
2020
Q2
$240 Hold
920
0.01% 106
2020
Q1
$200K Hold
920
0.03% 105
2019
Q4
$221K Sell
920
-200
-18% -$44.1K 0.03% 103
2019
Q3
$248K Hold
1,120
0.03% 96
2019
Q2
$248K Hold
1,120
0.04% 100
2019
Q1
$248K Hold
1,120
0.04% 97
2018
Q4
$248K Hold
1,120
0.04% 94
2018
Q3
$248K Hold
1,120
0.04% 92
2018
Q2
$248K Sell
1,120
-200
-15% -$35.4K 0.04% 86
2018
Q1
$292K Hold
1,320
0.05% 73
2017
Q4
$230K Sell
1,320
-411
-24% -$72.7K 0.03% 102
2017
Q3
$323K Buy
1,731
+411
+31% +$72.8K 0.05% 84
2017
Q2
$227K Hold
1,320
0.03% 106
2017
Q1
$217K Buy
+1,320
New +$219K 0.03% 107
2016
Q4
Sell
-1,320
Closed -$220K 113
2016
Q3
$220K Buy
+1,320
New +$223K 0.04% 102

Other funds holding AMGN

Nottingham Advisors's AMGN Position: Q2 2023 in Review

Nottingham Advisors sold out of Amgen (AMGN) in Q2 2023, closing a stake of 920 shares — an estimated $222K sold.

Nottingham Advisors first reported a position in AMGN in Q3 2016 and held it in 24 quarters. The position peaked at $323K in Q3 2017. 2,390 funds tracked by Wall St. Rank hold AMGN as of Q2 2023.

  • Nottingham Advisors reported no remaining Amgen position as of Q2 2023 after selling out during the quarter.
  • Nottingham Advisors sold 920 Amgen shares in Q2 2023, an estimated $222K.
  • Nottingham Advisors first reported a position in Amgen in Q3 2016 and held it in 24 quarters.
  • Nottingham Advisors's Amgen position peaked at $323K in Q3 2017.
  • 2,390 funds tracked by Wall St. Rank held Amgen as of Q2 2023.

Based on Nottingham Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.